Lv3
400 积分 2021-10-14 加入
80O Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: Sub-analysis from the pivotal phase III IMpower010 study
2小时前
待确认
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
3个月前
已完结
Unlocking the future of cancer diagnosis – promises and challenges of ctDNA-based liquid biopsies in non-small cell lung cancer
4个月前
已完结
Imaging in Lung Cancer Staging
5个月前
已完结
Liquid Biopsy of Lung Cancer Before Pathological Diagnosis Is Associated With Shorter Time to Treatment
5个月前
已完结
Liquid biopsy in lung cancer
5个月前
已完结
Rapid Advances in Resectable Non–Small Cell Lung Cancer
5个月前
已完结
Lineage-specific intolerance to oncogenic drivers restricts histological transformation
7个月前
已完结
Transforming lung cancer types
7个月前
已完结
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
7个月前
已完结
皖公网安备34019202002308
